Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Investor Wire

INCY Quote, Trading Chart, Incyte Corporation


home / stock / incy / incy quote

$78.66 Last:

0.27% Change Percent:

$79.17 Open:

$78.66 Previous Close:

$79.64 High:

$77.77 Low:

1,691,481 Volume:

02/26/2021 04:55:40 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2021-02-2679.1778.6679.6477.771,691,481
2021-02-2579.8578.4580.6477.741,072,809
2021-02-2479.8880.6182.7579.341,857,533
2021-02-2379.1779.0279.6576.692,477,074
2021-02-2280.0279.9280.4978.911,746,739
2021-02-1982.0280.5482.4880.321,552,293
2021-02-1883.0581.5583.0579.821,939,297
2021-02-1782.0683.7784.0580.51,608,716
2021-02-1684.9982.1384.9981.851,170,891
2021-02-1584.9984.32585.283.1951,153,771
2021-02-1284.9984.32585.283.1951,153,754
2021-02-1186.0484.9986.7384.60591,060,509
2021-02-1087.585.1788.1484.082,230,497
2021-02-0994.3489.4694.501589.241,356,726
2021-02-0891.0893.6293.7190.11,000,150
2021-02-0591.6390.2491.7901,233,740
2021-02-0491.1690.9192.58590.53881,052
2021-02-039390.9793.8190.8895,932
2021-02-0292.193.0594.1991.421,385,698
2021-02-019090.9291.489.35995,397
Stock Information

Incyte Corporation Company Name:

INCY Stock Symbol:

NASDAQ Market:

Incyte Corporation Website:

INCY Quote, Trading Chart, Incyte Corporation

MENU
INCY INCY Quote INCY Short INCY News INCY Articles INCY Message Board
Get INCY Alerts

News, Short Squeeze, Breakout and More Instantly...

Stock Investor Wire
RECENT INCY NEWS
  • INCY - Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)

    Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who ...

  • INCY - Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease

    Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi ® ) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult ...

  • INCY - Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

    Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, as a treatment for atopic dermatitis (AD), a typ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Sign up or login to continue

Sign up or login to continue.


Forgot password?




WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News